Frataxin inactivation leads to steroid deficiency in flies and human ovarian cells . Amandine Palandri, David L'hôte, Joëlle Cohen-Tannoudji, Hervé Tricoire and Véronique Monnier; Hum. Mol. Genet. (2015) doi: 10.1093/hmg/ddv024 First published online: January 26, 2015
Friday, January 30, 2015
Reata Enrolls First Patient in the MOXIe Study, a Phase 2/3 Study Examining RTA 408 in Friedreich's Ataxia Patients
Reata Enrolls First Patient in the MOXIe Study, a Phase 2/3 Study Examining RTA 408 in Friedreich's Ataxia Patients. SOURCE: Reata Pharmaceuticals, Inc., January 29
IRVING, TX--(Marketwired - January 29, 2015) - Reata announces enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Oral Capsules versus placebo for the treatment of patients with Friedreich's ataxia.
IRVING, TX--(Marketwired - January 29, 2015) - Reata announces enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Oral Capsules versus placebo for the treatment of patients with Friedreich's ataxia.
Subscribe to:
Posts (Atom)
